Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 198

1.

Modulation of ventricular fibrillation in isolated perfused heart by dofetilide.

Amitzur G, Shenkar N, Leor J, Novikov I, Eldar M.

J Cardiovasc Pharmacol. 2003 Jun;41(6):838-48.

PMID:
12775960
2.

Role of sodium channels in ventricular fibrillation: a study in nonischemic isolated hearts.

Amitzur G, Schoels W, Visokovsky A, Lev-Ran V, Novikov I, Mueller M, Kraft P, Kaplinsky E, Eldar M.

J Cardiovasc Pharmacol. 2000 Dec;36(6):785-93.

PMID:
11117380
3.
4.

Refractoriness and conduction interaction during modulation of non-ischemic ventricular fibrillation by flecainide.

Amitzur G, Shenkar N, Mueller M, Kraft P, Novikov I, Eldar M, Leor J, Raichlin E, Schoels W.

Cardiovasc Drugs Ther. 2003 May;17(3):237-47.

PMID:
14574082
5.

Modulation of ventricular fibrillation in the isolated heart: the role of slow calcium channel activity under continuous perfusion.

Amitzur G, Pogatz V, Novikov I, Kaplinsky E, Eldar M.

J Cardiovasc Pharmacol. 2000 Jan;35(1):16-28.

PMID:
10630729
6.

Effects of the class III antiarrhythmic agent dofetilide (UK-68,798) on L-type calcium current from rabbit ventricular myocytes.

Paul AA, Leishman DJ, Witchel HJ, Hancox JC.

J Pharm Pharmacol. 2001 Dec;53(12):1671-8.

PMID:
11804397
7.

Dofetilide effects on the inhibition by trains of subthreshold conditioning stimuli.

Chorro FJ, Sanchis J.

Pacing Clin Electrophysiol. 2004 Mar;27(3):327-32.

PMID:
15009858
8.

In vitro and in vivo effects of the atrial selective antiarrhythmic compound AVE1231.

Wirth KJ, Brendel J, Steinmeyer K, Linz DK, Rütten H, Gögelein H.

J Cardiovasc Pharmacol. 2007 Apr;49(4):197-206.

PMID:
17438404
9.

Dofetilide promotes repolarization abnormalities in perfused Guinea-pig heart.

Osadchii OE.

Cardiovasc Drugs Ther. 2012 Dec;26(6):489-500. doi: 10.1007/s10557-012-6405-1.

PMID:
22918600
10.

Acidification alters antiarrhythmic drug blockade of the ether-a-go-go-related Gene (HERG) Channels.

Dong DL, Li Z, Wang HZ, Du ZM, Song WH, Yang BF.

Basic Clin Pharmacol Toxicol. 2004 May;94(5):209-12.

11.

Effects of EGIS-7229 (S 21407), a novel class III antiarrhythmic drug, on myocardial refractoriness to electrical stimulation in vivo and in vitro.

Kovács A, Gyönös I, Magyar J, Bányász T, Nánási PP, Spedding M, Szénási G.

J Cardiovasc Pharmacol. 2001 Jan;37(1):78-88.

PMID:
11152377
12.

Dofetilide reduces the incidence of ventricular fibrillation during acute myocardial ischaemia. A randomised study in pigs.

Andersen HR, Wiggers H, Knudsen LL, Simonsen I, Thomsen PE, Christiansen N.

Cardiovasc Res. 1994 Nov;28(11):1635-40.

PMID:
7842456
13.

Comparison of the rate dependent effects of dofetilide and ibutilide in the newborn heart.

Pickoff AS, Stolfi A.

Pacing Clin Electrophysiol. 2001 May;24(5):816-23.

PMID:
11388101
15.

Atrial effects of the novel K(+)-channel-blocker AVE0118 in anesthetized pigs.

Wirth KJ, Paehler T, Rosenstein B, Knobloch K, Maier T, Frenzel J, Brendel J, Busch AE, Bleich M.

Cardiovasc Res. 2003 Nov 1;60(2):298-306.

16.

Three things you should know when considering the atria: location, location, location.

Boyden PA.

Circ Res. 2001 Jun 8;88(11):1097-8. No abstract available.

18.

"Early" class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat.

Blaauw Y, Gögelein H, Tieleman RG, van Hunnik A, Schotten U, Allessie MA.

Circulation. 2004 Sep 28;110(13):1717-24. Epub 2004 Sep 13.

19.

Block of HERG-carried K+ currents by the new repolarization delaying agent H 345/52.

Amos GJ, Jacobson I, Duker G, Carlsson L.

J Cardiovasc Electrophysiol. 2003 Jun;14(6):651-8.

PMID:
12875428
20.
Items per page

Supplemental Content

Write to the Help Desk